Leverette 21 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol supplies the estrogen component of the combination, stabilizing the endometrial lining and contributing to the suppression of the hypothalamic‑pituitary‑ovarian axis. This estrogenic activity works together with levonorgestrel’s progestogenic effect to inhibit ovulation, thicken cervical mucus, and create an endometrial environment that is less receptive to implantation.

The exact dosing schedule for Leverette 21 is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for 21 consecutive days followed by a hormone‑free interval, but the prescriber will set the precise regimen based on individual patient needs and clinical guidelines.

Leverette 21 is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it may cause fetal harm. It is also not recommended during breastfeeding, as hormonal exposure could affect milk production and infant development. Women should discontinue use if they become pregnant and consult a physician before breastfeeding.

To request Leverette 21, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Leverette 21 contains the standard dose of ethinylestradiol combined with levonorgestrel, a widely used progestogen. Its efficacy, safety profile, and side‑effect spectrum are comparable to other second‑generation combined pills. Differences among products usually relate to the specific estrogen dose, progestogen type, and formulation characteristics, which may influence tolerability for individual patients.

Store Leverette 21 at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not store in the bathroom or near heat sources.

Leverette 21 is taken orally, usually one tablet each day at the same time. The typical regimen involves 21 consecutive active tablets followed by a 7‑day hormone‑free interval, during which a withdrawal bleed occurs. Patients should follow the prescriber’s instructions and start a new pack immediately after the interval.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis leading to stroke or myocardial infarction, and severe hypertension. Liver disorders and rare allergic reactions can also occur. Patients should seek immediate medical attention if they experience symptoms such as unexplained leg pain, chest pain, severe headache, or jaundice.

Leverette 21 is contraindicated in women who are pregnant, have a history of thromboembolic disease, uncontrolled hypertension, active liver disease, or known hypersensitivity to any component. It should also be avoided by smokers over 35 years of age and by women with migraine with aura due to the increased risk of vascular events.